Sandbox Try 002
From Proteopedia
(Difference between revisions)
(One intermediate revision not shown.) | |||
Line 1: | Line 1: | ||
- | + | <StructureSection load='' size='450' side='right' scene='10/1064672/010_Fig_1a_pse/1' caption='Overall structure of HpGluRS monomer [[6b1p]] in rainbow color from blue N-terminus to red C-terminus. | |
- | <StructureSection load=' | + | '> |
- | + | ===Crystal structure of glutamyl-tRNA synthetase from H''elicobacter pylori''=== | |
- | + | <big>Dr Oluwatoyin A. Asojo</big> <ref>doi: 10.1107/S2053230X24011099</ref> | |
- | + | <hr/> | |
- | + | <b>Molecular Tour</b><br> | |
- | < | + | ''Helicobacter pylori'' is one of the most common bacterial infections; over two-thirds of the world’s population is infected by early childhood. Persistent ''H. pylori'' infection results in gastric ulcers and cancers. Due to drug resistance, there is a need to develop alternative treatments to clear ''H. pylori''. The Seattle Structural Genomics Center for Infectious Disease (SSGCID) conducts structure-function analysis of potential therapeutic targets from ''H. pylori''. Glutamyl-tRNA synthetase (GluRS) is essential for tRNA aminoacylation and is under investigation as a bacterial drug target. The SSGCID produced, crystallized, and determined the <scene name='10/1064672/010_fig_1a_png/1'>apo structure of H. pylori</scene> GluRS (HpGluRS). HpGluRS has the prototypical bacterial GluRS topology, similar binding sites, and tertiary structures with other bacterial GluRS that are promising drug targets. ENDScript<ref>PMID:12824317</ref><ref>PMID:24753421</ref> analysis reveals that HpGluRS is a prototypical bacterial GluRS shown showing sequence conservation as a <scene name='10/1064672/010_fig_1b_png/1'>ribbon diagram</scene> and <scene name='10/1064672/010_fig_1c_png/1'>solvent-accessible surface area</scene> Residues involved in glutamate binding are well conserved with ''Pseudomonas aeruginosa'' GluRS (PaGluRS), which has been studied to develop promising new inhibitors for Pseudomonas aeruginosa. These structural similarities can be exploited for drug discovery and repurposing to generate new antibacterials to clear persistent ''H. pylori'' infection and reduce gastric ulcers and cancer. |
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
- | + | ||
+ | <b>References</b> | ||
+ | <references/> | ||
</StructureSection> | </StructureSection> | ||
- | + | __NOEDITSECTION__ | |
- | + |
Current revision
|